Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 11/20 | 0.58 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 2/20 | 0.47 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971235 | 0.93 | SGK1 (0.56) | SGK1MAP2K4 | |
| SCHEMBL3964181 | 0.92 | SGK1 (0.57) | SGK1MAP2K4 | |
| SCHEMBL3968444 | 0.91 | MAP2K4 (0.49) | SGK1MAP2K4 | |
| SCHEMBL3962444 | 0.87 | SGK1 (0.61) | SGK1MAP2K4ITGA1 | |
| SCHEMBL3967746 | 0.87 | MAP2K4 (0.55) | SGK1MAP2K4 | |
| SCHEMBL3972626 | 0.87 | MAP2K4 (0.52) | SGK1MAP2K4ACLY | |
| SCHEMBL3970942 | 0.87 | MAP2K4 (0.56) | SGK1MAP2K4 | |
| SCHEMBL3968695 | 0.86 | TP53 (0.58) | SGK1ALPL | |
| SCHEMBL3968870 | 0.86 | MAP2K4 (0.56) | MAP2K4 | |
| SCHEMBL3963379 | 0.85 | MAP2K4 (0.56) | SGK1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | SGK1 457/4885MAP2K4 101/4885HSP90AA1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.